Breast Cancer

The aim of the Breast Cancer Clinical Group is to oversee, support and bring together the viewpoints of all of the multi-disciplinary teams working in breast cancer services across the Network.

The group aims to ensure the same standard of care and treatment for all breast cancer patients across the Thames Valley.

There are two group leads and they are:
Dr Sileida Oliveros, Consultant Clinical Oncologist, Oxford University Hospitals NHS Foundation Trust
and
Mr Giles Cunnick, Consultant Breast Surgeon, Bucks Healthcare Trust.

The next Thames Valley Breast Group meeting is scheduled for Monday 11th March 2019, 14:30-16:30 at The Oxford Science Park, Magdalen Centre, Robert Robinson Ave, Oxford OX4 4GA.

Breast SACT regimens (all PDF format)

Breast chemotherapy regimens v4.2 (November 2018) – superseded: for patients who have already started treatment only

Interim -Trastuzumab emtansine

Covid -19 interim breast regimens

Pertuzumab Trastuzumab IV (neoadjuvant)
Paclitaxel albumin bound Trastuzumab
Capecitabine Pertuzumab Trastuzumab (metastatic)
Pertuzumab Trastuzumab IV (metastatic)

Neoadjuvant

Docetaxel Carboplatin Pertuzumab Trastuzumab (neoadjuvant node negative or unknown nodal status)
Docetaxel Carboplatin Pertuzumab Trastuzumab (neoadjuvant node positive)
EC Docetaxel
EC Docetaxel Pertuzumab Trastuzumab (neoadjuvant node negative or unknown nodal status)
EC Docetaxel Pertuzumab Trastuzumab (neoadjuvant node positive)
EC Docetaxel Trastuzumab
EC Paclitaxel (dose dense)
EC Paclitaxel Carboplatin
Paclitaxel albumin-bound (nab-paclitaxel)
Paclitaxel weekly

Adjuvant

Docetaxel Carboplatin Pertuzumab Trastuzumab (adjuvant)
Docetaxel Carboplatin Trastuzumab
Docetaxel Cyclophosphamide
EC
EC Docetaxel
EC Docetaxel Pertuzumab Trastuzumab (adjuvant)
EC Docetaxel Trastuzumab
EC Paclitaxel (dose dense)
EC Paclitaxel Carboplatin
Neratinib
Paclitaxel albumin-bound (nab-paclitaxel)
Paclitaxel weekly
Paclitaxel weekly Pertuzumab Trastuzumab
Paclitaxel weekly Trastuzumab
Pertuzumab Trastuzumab
Interim -Trastuzumab emtansine

Metastatic

Abemaciclib Fulvestrant
Abemaciclib with aromatase inhibitor
Capecitabine
Carboplatin
Cyclophosphamide Methotrexate
Docetaxel
Docetaxel Pertuzumab Trastuzumab
EC
Epirubicin weekly
Eribulin
Everolimus
Fulvestrant (local funding)

Gemcitabine Carboplatin

Interim Atezolizumab Paclitaxel albumin-bound

MMM
Paclitaxel Carboplatin
Paclitaxel (weekly for 3 weeks then 1 week off)
Paclitaxel albumin-bound (nab-paclitaxel)
Palbociclib Fulvestrant
Palbociclib with aromatase inhibitor
Ribociclib Fulvestrant
Ribociclib with aromatase inhibitor
Trastuzumab emtansine
Trastuzumab monotherapy
Vinorelbine oral

For further information please contact us.